RxDoctor Payments Data

Sarah Matovu, MD

Family Medicine · Macon, GANPI 1508832825

Payments from drug & device makers

$518in general payments, 2019–2025

Across 17 payments — averaging $30.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$131
  • Exact Sciences$124
  • Scilex Pharmaceuticals Inc.$57
  • Novartis$36
  • Novo Nordisk$30
  • Alnylam Pharmaceuticals Inc.$28
  • plus $113 from 8 others

What the payments were for

  • Food & beverage$518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$518 in reported general payments places this provider in the 45th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$372
Medicare patients
17
Services billed
60

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide295$310,121
LinzessLinaclotide162$130,028
EliquisApixaban138$105,084
MounjaroTirzepatide56$66,036
MyrbetriqMirabegron85$51,201
TradjentaLinagliptin51$47,899
FarxigaDapagliflozin Propanediol56$47,311
JardianceEmpagliflozin40$40,034
JanuviaSitagliptin Phosphate39$34,859
JanumetSitagliptin Phos/Metformin Hcl36$34,455
SymbicortBudesonide/Formoterol Fumarate66$22,811
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen684$20,693
TrulicityDulaglutide21$20,470
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$18,287
Spiriva RespimatTiotropium Bromide22$17,882

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$30$324,317310 claims
AbbVieLinzess$13$130,028162 claims
Boehringer IngelheimTradjenta, Jardiance, Spiriva Respimat, Combivent Respimat$13$117,565129 claims
PfizerEliquis$13$105,084138 claims
MerckJanuvia, Janumet, Belsomra$14$77,41193 claims
GSKTrelegy Ellipta, Breo Ellipta$14$28,16941 claims
Johnson & JohnsonXarelto$17$13,75720 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$17$7,77612 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$12$5,15011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →